Bristol-Myers Squibb BMY Opdivo Qvantig — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's opdivo qvantig — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's opdivo qvantig — total revenues?
- Bristol-Myers Squibb (BMY) reported opdivo qvantig — total revenues of $261M in Q2 2026.
- How has Bristol-Myers Squibb's opdivo qvantig — total revenues changed year-over-year?
- Bristol-Myers Squibb's opdivo qvantig — total revenues increased by 770.0% year-over-year, from $30M to $261M.
- What does opdivo qvantig — total revenues mean?
- This metric represents the total net sales generated by the Opdivo product line, a cornerstone of the company's immuno-oncology portfolio. It reflects the market adoption and commercial performance of this specific therapeutic asset across its approved indications. Monitoring this revenue stream is essential for assessing the company's competitive position in the oncology market and the lifecycle maturity of its flagship immunotherapy treatments.